Skip to content
S3518Senate2023-2024 SessionSame asA895

Expose Delayed Generic Drugs

Official title

“Enacts the manufacturer disclosure and transparency act”

Status
In Assembly Committee
Consumer Affairs And Protection
Impact
7/10
Significant
Passage
0%

Bill progress

Step 5 of 7

In Assembly · Consumer Affairs And Protection

What's happening

This bill requires drug manufacturers to notify the attorney general of agreements that delay generic drugs and imposes penalties for noncompliance.

Why it matters

  1. Shines a light on "pay-for-delay" deals. By requiring manufacturers to disclose agreements that postpone generic drugs, the law aims to expose deals that can keep drug prices high and limit consumer access to affordable medications.

  2. Enables faster public and institutional response. The requirement for the Attorney General to share information with Medicaid, health plans, and pharmacy benefit managers within 30 days ensures that health systems and payers are quickly informed and can adjust policies, pricing, or coverage decisions accordingly.

  3. Promotes public transparency and accountability. Making all disclosures publicly available and easily searchable empowers patients, advocacy groups, and researchers to track which drugs are being delayed and hold companies accountable for actions that affect drug affordability.

  4. Creates significant financial deterrents. Substantial daily fines for noncompliance provide a strong incentive for drug makers to comply with the law, which could discourage secretive arrangements that harm competition and delay lower-cost generics.

The daily · weekday mornings

Albany, before your first meeting.

Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.

Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.

Who cares

  • Brand-name prescription drug manufacturers

    Those doing business in New York would have to report arrangements delaying or preventing generic competition within 30 days, with daily fines for knowingly or negligently failing to notify the attorney general.

  • New York attorney general’s office

    The office would collect disclosures, share them within 30 days, publish searchable notices online and impose fines for reporting violations.

  • Drug utilization review board, Medicaid managed care plans, health carriers and pharmacy benefits managers

    They would receive disclosures identifying affected drugs, wholesale prices, manufacturers, diseases treated and the length of generic delays.

  • Patients prescribed brand-name drugs

    They could search public notices for arrangements delaying generic substitutes by drug, cost, disease and manufacturer.

Headline styles

Expose Delayed Generic Drugs

Plain English, a few words. Used as the page title.

Sponsors

Primary sponsor
Nathalia Fernandez

Senator · Senate District 34

Chair, Alcoholism And Substance Use Disorders

History

  1. Referred to consumer affairs and protection
  2. Delivered to assembly
  3. Passed senateVote 50–12
  4. Advanced to third reading
  5. 2nd report cal.
  6. 1st report cal.112
  7. Referred to consumer protection
  8. Referred to consumer protection

Companion bill

The same bill in the other chamber. A bill becomes law when one version passes both houses and the governor signs it, so either number can carry it.

A895Assembly

Require Drug Deal Disclosure

In Assembly Committee · Consumer Affairs And Protection · Sponsor Emily Gallagher

Impact 7 · Significant0% to pass

Full text

2 pagesUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗

STATE OF NEW YORK

3518

2023-2024 Regular Sessions

IN SENATE

January 31, 2023

Introduced by Sen. FERNANDEZ -- read twice and ordered printed, and when printed to be committed to the Committee on Consumer Protection

AN ACT to amend the general business law, in relation to requiring prescription drug manufacturers to notify the attorney general of arrangements between pharmaceutical manufacturers resulting in the delay of the introduction of generic drugs

The People of the State of New York, represented in Senate and Assembly, do enact as follows:

Section 1. This act shall be known and may be cited as the "manufacturer disclosure and transparency act".

§ 2. The general business law is amended by adding a new section 396- rrr to read as follows:

§ 396-rrr. Delay of introduction of generic medications. 1. (a) Each pharmaceutical manufacturer doing business in this state that manufactures a brand name prescription drug and enters into an arrangement, through agreement or otherwise, with another pharmaceutical manufacturer that has the purpose or effect of delaying or preventing such other manufacturer from introducing a generic substitute for such drug into the marketplace shall, not later than thirty days after entering into such arrangement, send notice to the attorney general, in a form and manner prescribed by the attorney general, disclosing the name of such drug, the wholesale price, the disease such drug is commonly prescribed to treat, the manufacturer of such drug, the name of the generic manufacturer, and the length of the delay.

(b) The attorney general shall, no later than thirty days after receiving a notice pursuant to paragraph (a) of this subdivision, share the information with the drug utilization review board established under section three hundred sixty-nine-bb of the social services law, all medicaid managed care plans, health carriers and pharmacy benefits managers doing business in the state in a format and manner prescribed by the attorney general.

EXPLANATION--Matter in italics (underscored) is new; matter in brackets

[ ] is old law to be omitted.

LBD00235-01-3

2. The office of the attorney general shall post on its website all the notices required pursuant to paragraph (a) of subdivision one of this section in a format and manner developed by the attorney general that is searchable by drug, cost, disease, and manufacturer both for the brand and generic drug for public review.

3. For a violation by a manufacturer of a brand name drug who knowingly or negligently fails to notify the attorney general as required in paragraph (a) of subdivision one of this section, the attorney general shall fine such manufacturer no less than five thousand dollars for the first violation for each day such manufacturer fails to properly notify the attorney general pursuant to the requirements of this section and no less than ten thousand dollars for each violation thereafter for each day such manufacturer fails to properly notify the attorney general pursuant to the requirements of this section.

4. The attorney general is authorized to promulgate rules and regulations necessary for the implementation of this section.

§ 3. This act shall take effect on the one hundred eightieth day after it shall have become a law.

Reflowed for reading: line numbers and page breaks removed. Cite the official text.

Sponsor's memo

Title of bill

An act to amend the general business law, in relation to requiring prescription drug manufacturers to notify the attorney general of arrangements between pharmaceutical manufacturers resulting in the delay of the introduction of generic drugs

Purpose or general idea of bill

Enacts the "Manufacturer Disclosure and Transparency Act" to bring disclosure and transparency to the pay-for-delay deals that harm consum- ers by delaying generic drug competition with brand-name drugs.

Summary of provisions

Section 1 establishes the title of the bill.

Read the full memo (775 words)

Section 2 requires each pharmaceutical manufacturer doing business in this state that manufactures a brand-name prescription drug and enters into an agreement with another pharmaceutical manufacturer for the purpose of delaying or preventing another manufacturer from introducing a generic substitute for a brand-name drug to, no later than thirty days after entering into such agreement, send notice to the Attorney General with the name of the drug, the wholesale price, the disease it is commonly prescribed to treat the manufacturer of such drug, the name of the generic manufacturer and the length of the delay. The Attorney General is then required to share that information with the New York State Drug Utilization Review Board, all Medicaid managed care plans, health carriers and pharmacy benefit managers doing business in the state. The Attorney General's office shall also post on its website all the notices required in section 2 searchable by drug, cost, disease and manufacturer both for the brand-name and generic drug for public review. A manufacturer of a brand-name drug who fails to notify the Attorney General of any agreement specified in the act shall be fined by the Attorney General no less than five-thousand dollars for a f irst violation and no less than ten-thousand dollars for each violation ther- eafter for each day such manufacturer fails to properly notify the attorney general pursuant to the requirements of the section. Addi- tionally, the Attorney General is authorized to promulgate rules and regulations necessary for the implementation of this section.

Section 3 establishes the effective date.

Justification

The Manufacturer Disclosure and Transparency Act would bring transparen- cy and disclosure to the pay-for-delay deals that harm consumers by delaying generic drug competition with brand-name drugs. Rising prescription drug prices have been devastating to New Yorkers who depend on prescription drugs to keep them healthy. The growing number of brand name and specialty drugs with prices of $100,000 or more has led many to question whether the costs associated with these products are defensible or sustainable. The timely availability of generic and biosimilar drugs, which will increase competition and help lower prices - will play an important role in addressing these concerns.

Brand-name drug manufacturers often file patent infringement lawsuits against the first generic drug manufacturers to seek FDA approval for competing generic drugs. Rather than face the costs and uncertainty associated with litigation, some brand-name and generic drug manufactur- ers choose to enter into what is known as a "pay-for-delay" agreement where the brand-name drug manufacturers compensate the generic drug manufacturer for keeping its product off the market for a certain amount of time. Such agreements can be particularly problematic when they involve the first-to-file generic manufacturer, because no other generic manufacturer can enter the market until the first-to-file manufacturer has marketed its product for 180 days.

These pay-for-delay agreements provide financial benefits to drug manufacturers at the expense of consumers; the brand-name manufacturer can continue to charge monopoly prices, and the generic company is compensated for its inaction. The Federal Trade Commission (FTC) esti- mates that pay-for delay agreements cost American consumers $3.5 billion per year.

The FTC has found that pay-for-delay agreements prohibit generic entry for an average of nearly 17 months longer than patent settlement agree- ments without such payments. In the meantime, consumers must continue paying brand-name drug prices, which can be as much as 85 percent higher than the prices of their generic drug counterparts. Any delay in gener- ic entry results in a longer period of purchases at the full brand price and correspondingly fewer purchases at less expensive generic prices. This negatively impacts both consumers and other payers, including taxpayer-funded health programs such as Medicaid.

Generic drugs have proven to be one of the safest and most effective ways for consumers to lower their prescription drug costs, and the use of generic drugs has been steadily increasing. These drugs should not be delayed from entering the marketplace.

Prior legislative history

2021-2022: S398 / A8824

2019-2020: S5169 / A7196

Fiscal implications

None

Effective date

This act shall take effect one the one hundred eightieth day after it shall have come a law.

Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.